Brean Murray Carret & Co. Maintains a 'Buy' on Dendreon (DNDN); MEDCAC Panel Docs Relatively Benign
Tweet Send to a Friend
Brean Murray Carret & Co. maintains a 'Buy' on Dendreon (NASDAQ: DNDN), PT $65.
Brean analyst says, "TheMEDCAC panel briefing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says, "TheMEDCAC panel briefing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
